Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2017-02-15T08:02:43Z | - |
dc.date.available | 2017-02-15T08:02:43Z | - |
dc.date.issued | 2007 | * |
dc.identifier.issn | 0363-9045 | * |
dc.identifier.other | OAK-4260 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/234456 | - |
dc.description.abstract | Doxazosin mesylate is a selective alpha-adrenoreceptor antagonist for the treatment of hypertension and benign prostatic hyperplasia. A simple high performance liquid chromatographic method has been developed and validated for the quantitative determination of doxazosin in plasma. A reversed phase C18 column was used for the separation of doxazosin and prazosin (internal standard) with a mobile phase composed of water • acetonitrile • triethylamine (68:32:0.2 v/v, pH 5.0) at a flow rate of 1.2 mL/min. The fluorescence detector was operated at 246 (excitation) and 389 nm (emission). Intra- and inter-day precision and accuracy were acceptable for all quality control samples including the lower limit of quantification of 1 ng/mL. Recovery of doxazosin from human plasma was greater than 93.4%. Doxazosin was stable in human plasma under various storage conditions. This method was used successfully for a pharmacokinetic study in plasma after oral administration of multiple 4-mg dose of doxazosin gastrointestinal therapeutic system formulation to 16 healthy volunteers. At steady state the mean area under the curve for a dosing interval and elimination half-life were calculated to be 367.0 ± 63.5 ng·hr/mL and 29.2 ± 4.5 hr, respectively. There was no difference in pharmacokinetic parameters between male and female. Copyright © Informa Healthcare USA, Inc. | * |
dc.language | English | * |
dc.title | Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 33 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 824 | * |
dc.relation.lastpage | 829 | * |
dc.relation.journaltitle | Drug Development and Industrial Pharmacy | * |
dc.identifier.doi | 10.1080/03639040601012999 | * |
dc.identifier.wosid | WOS:000249247000003 | * |
dc.identifier.scopusid | 2-s2.0-34548299764 | * |
dc.author.google | Kwon Y.H. | * |
dc.author.google | Gwak H.S. | * |
dc.author.google | Yoon S.J. | * |
dc.author.google | Chun I.K. | * |
dc.date.modifydate | 20240422115307 | * |